v3.26.1
Segment Reporting - Summary of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
REVENUES:    
Total revenues $ 392,911 $ 306,510
EXPENSES:    
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) 61,578 49,197
Development programs:    
Alixorexton 25,497 17,854
LYBALVI 4,449 3,852
LUMRYZ 2,923 0
Other external R&D expenses 17,960 10,973
Total external R&D expenses 50,829 32,679
Internal R&D expenses:    
Employee-related 43,615 31,354
Occupancy 3,264 3,148
Depreciation 1,688 1,467
Other internal R&D expenses 3,949 3,169
Total internal R&D expenses 52,516 39,138
R&D expenses 103,345 71,817
Selling, general and administrative expenses:    
Selling and marketing expense 155,563 122,934
General and administrative expense 109,030 48,770
Total selling, general and administrative expense 264,593 171,704
Other segment (expense) income [1] (29,875) 8,672
NET (LOSS) INCOME $ (66,480) $ 22,464
[1] “Other segment (expense) income” during the three months ended March 31, 2026 and 2025, includes “Amortization of acquired intangible assets”, “Other (expense) income, net” and “Income tax provision”.